Skip to main content
Journal cover image

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Publication ,  Journal Article
Freedman, AN; Sansbury, LB; Figg, WD; Potosky, AL; Weiss Smith, SR; Khoury, MJ; Nelson, SA; Weinshilboum, RM; Ratain, MJ; McLeod, HL; Liu, G ...
Published in: J Natl Cancer Inst
November 17, 2010

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

November 17, 2010

Volume

102

Issue

22

Start / End Page

1698 / 1705

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Survivors
  • Retrospective Studies
  • Public Sector
  • Private Sector
  • Precision Medicine
  • Pharmacogenetics
  • Pharmacoepidemiology
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Freedman, A. N., Sansbury, L. B., Figg, W. D., Potosky, A. L., Weiss Smith, S. R., Khoury, M. J., … Minasian, L. M. (2010). Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst, 102(22), 1698–1705. https://doi.org/10.1093/jnci/djq390
Freedman, Andrew N., Leah B. Sansbury, William D. Figg, Arnold L. Potosky, Sheila R. Weiss Smith, Muin J. Khoury, Stefanie A. Nelson, et al. “Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.J Natl Cancer Inst 102, no. 22 (November 17, 2010): 1698–1705. https://doi.org/10.1093/jnci/djq390.
Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17;102(22):1698–705.
Freedman, Andrew N., et al. “Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.J Natl Cancer Inst, vol. 102, no. 22, Nov. 2010, pp. 1698–705. Pubmed, doi:10.1093/jnci/djq390.
Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17;102(22):1698–1705.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

November 17, 2010

Volume

102

Issue

22

Start / End Page

1698 / 1705

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Survivors
  • Retrospective Studies
  • Public Sector
  • Private Sector
  • Precision Medicine
  • Pharmacogenetics
  • Pharmacoepidemiology
  • Oncology & Carcinogenesis